Pulse Biosciences, Inc.

Passed

Class Action Period:
January 12, 2021 - February 07, 2022

Lead Plaintiff Deadline:
April 18, 2022

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(1) the investigational device exemption study evaluating the use of the Company's CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints; (2) as a result, there was a substantial risk that the U.S. Food and Drug Administration would reject Pulse’s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until April 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.